How the FDA Impacts the Parkinson's Community

This informational webcast provides a unique opportunity to gain valuable insights into the FDA, the role it plays in therapy development, and possible areas for needed change and improvement.

Click here to watch a recorded archive of the webcast. [1]

Moderator:
Amy Comstock Rick, JD
CEO, Parkinson's Action Network

Panelists:
Marc Walton, MD, PhD [2]
Associate Director for Translational Medicine in the Office of Translational Sciences at the Center for Drug Evaluation and Research, FDA

Michelle McMurry-Heath, MD, PhD [3]
Associate Director for Science at the Center for Devices and Radiological Health, FDA

Cartier Esham, PhD [4]
Senior Director of Emerging Companies Health and Regulatory Affairs for the Biotechnology Industry Organization (BIO)

Jackie Christensen [5]
Patient-Representative to the Food and Drug Administration's Office of Special Health Issues

This program is made possible by a conference support grant awarded from and administered by the Telemedicine & Advanced Technology Research Center (TATRC) of the U.S. Army Medical Research & Materiel Command (USAMRMC), Award # W23RYX1067N603

This webcast was made possible in part by a grant from UCB.

With additional contributions from: